STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential

Pfizer's obesity drug berobenatide, acquired from Metsera, showed continued weight loss when transitioning from weekly to monthly dosing in a mid-stage study. Patients lost up to 12.1% of their weight by 28 weeks, but the rate lagged behind Eli Lilly's Zepbound trial results.